Imperilled glacier, COVID immunity and ‘touching’ the Sun
The latest science news, in brief.
Biotech Hub
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
PROTAC degrader–induced SWI/SNF inactivation abolishes DNA accessibility at enhancer elements of oncogenes and also tempers supra-physiologic expression of driver transcription factors, resulting in…
The future of global health, and mapping the unseen: Books in brief
Andrew Robinson reviews five of the week’s best science picks.
Dr. Shadman on the Safety Profile of a CD20-Directed CAR T-Cell Therapy in B-NHL and CLL
Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic…
Bronze Age genomes reveal migration to Britain
The genomes of hundreds of individuals who lived in Great Britain and in continental Europe during the Bronze Age provide evidence for a migration of people from the continent to southern Britain between 1000 and 875 bc. Ancient DNA shows changes in early European farmer ancestry.
Origin Agritech Developing Nutrition Enhanced Corn Using CRISPR Gene Editing, Business News
BEIJING, Dec. 23, 2021 /PRNewswire/ — Origin Agritech Ltd. (NASDAQ: SEED) (the “Company” or “Origin”), an agriculture technology company, announced today that it is developing nutritionally enhanced…
Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma, Business News
SINGAPORE and GUANGZHOU, China and LOS ANGELES, Dec. 23, 2021 /PRNewswire/ — Lion TCR Pte Ltd today announced that it has received Fast Track Designation from United States Food and Drug…
Eli Lilly shepherds its $1.1B contender through another PhIII challenge on the way to the FDA
Just 6 days after Eli Lilly execs ID’d its $1.1 billion atopic dermatitis drug lebrikizumab as one of its top late-stage drug candidates, the pharma giant has followed up with another round of…
Third Rock’s Ambys closes a megaround with the clinic still a ways off for its regenerative cells for liver disease
When Ambys Medicines, a Third Rock Ventures-backed regenerative play, launched in 2018, it came with some serious fanfare for its liver disease-focused approach. Now, after years of quiet development,…